Acadia Pharmaceuticals Inc. (ACAD) Financials
Key financial figures for Acadia Pharmaceuticals Inc. (Q2 2026).
Acadia Pharmaceuticals Inc. reported revenue of $308.0 million for Q2 FY2026, up 16.4% from the same period a year earlier. Net income was $31.5 million, or $0.18 per share. Operating margin came to 12.29%. Free cash flow for the period was $124.5 million. Across the last 5 reported quarters, quarterly revenue has risen from $264.6 million in Q2 FY2025 to $308.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Acadia Pharmaceuticals Inc. are on the SentiSense financials page.
- Revenue
- $308M
- Net Income
- $32M
- EPS
- $0.18
- Total Assets
- $1.7B
- Operating Cash Flow
- $101M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $308M | $32M | $0.18 | 12.29% | $124M |
| Q1 FY2026 | $268M | $4M | $0.02 | -1.72% | $29M |
| Q4 FY2025 | $284M | $274M | $1.60 | 6.12% | -$53M |
| Q3 FY2025 | $279M | $72M | $0.42 | 12.83% | $74M |
| Q2 FY2025 | $265M | $27M | $0.16 | 12.24% |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $1.1B | $391M | $2.29 | 9.78% | $105M |
| FY2024 | $958M | $226M | $1.36 | 24.1% | $157M |
| FY2023 | $726M | -$61M | -$0.37 | -10.1% | -$23M |
Frequently asked questions
What was Acadia Pharmaceuticals Inc.'s revenue last quarter?
Acadia Pharmaceuticals Inc. reported revenue of $308.0 million for Q2 FY2026, up 16.4% from the same period a year earlier.
Is Acadia Pharmaceuticals Inc. profitable?
Yes. Acadia Pharmaceuticals Inc. reported net income of $31.5 million for Q2 FY2026, a net margin of 10.23% on revenue.
How has Acadia Pharmaceuticals Inc.'s margin trended?
Operating margin was 12.29% in Q2 FY2026. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Acadia Pharmaceuticals Inc. generate?
Acadia Pharmaceuticals Inc. generated free cash flow of $124.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Acadia Pharmaceuticals Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.